NCT06021600View on ClinicalTrials.gov

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
LeukemiaMyelodysplastic SyndromesAcute Myeloid Leukemia
Interventions
DRUG

Cladribine

Given by PO and Given by IV (vein)

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT06021600 - A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine | Biotech Hunter | Biotech Hunter